European Union

Have your say on patent office service and quality

A new benchmarking survey from IAM will reveal how perceptions of the world’s top patent offices are changing

Have your say on patent office service and quality
China brushes off EU request for more information on controversial SEP decisions
8 Sep 2021

China brushes off EU request for more information on controversial SEP decisions

Response to a formal inquiry under the WTO’s TRIPS mechanism will frustrate those pushing for greater clarity on ASI decisions

English Court of Appeal brings sufficiency test into line with EPO case law
7 Sep 2021

English Court of Appeal brings sufficiency test into line with EPO case law

A recent UK judgment is good news for owners of patents claiming large numbers of compounds

Latest

View all
11 Aug 2021

Pharma should make good use of the UPC from the beginning, says Bayer’s head of IP

There are a lot of potential benefits to the new system, but we need to integrate it into our strategies to make sure it works, explains Joerg Thomaier Read more

20 Jul 2021

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

The number and value of acquisitions have both tumbled further than in the early months of 2020 Read more

8 Jul 2021

New SPC data demonstrates the commercial power of patent extension rights in Europe

A recent report into supplementary protection certificates provides crucial insights for IP strategists and policy-makers Read more

7 Jul 2021

The EU wants answers on Chinese SEP patent practice

A request for information filed through the WTO signals high-level interest in how courts in China are handling anti-suit injunctions Read more

Designs

View all
18 Dec 2019

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

25 Sep 2019

Copyright clarification from Europe’s top court

Judges at the Court of Justice of the European Union delivered good news for designers in their Cofomel decision earlier this month Read more

3 Jul 2019

Law firm’s patent attorney deal shows changing face of IP practice in the UK

Lewis Silkin’s acquisition of Ablett & Stebbing is a first and demonstrates just how far things have moved in a once conservative market Read more

12 Oct 2017

Effective use of Community design protection

Design protection has taken on an increasingly important role in recent years, since appearance and exterior shape now play a fundamental role in the success of a product. Designs are now relevant to a wide range of products involving industry,… Read more

Finance

View all
22 Jun 2018

Qualcomm, France Brevets and IP Europe join forces to create a new funding initiative for European SMEs

A new financing and advisory mechanism to help innovative European SMEs secure high-quality patents and build effective portfolios will be rolled out across Europe in 2019, it was revealed today. The creation of Patent Factory Europe (PFE) was…

Read more

30 Aug 2016

Europe’s multi-billion dollar tax ruling against Apple throws treatment of IP assets into spotlight

The announcement today by the European Commission that Ireland must claw back €13 billion in tax revenues from Apple looks set to escalate the back and forth on the tax practices of major multinationals who use their economic leverage to benefit…

Read more

1 Aug 2016

The European patent market – where should investors look next?

A growing number of patent owners in the European Union probably have the potential to monetise their patents – but do they know the best way to go about this?

Read more

7 Jun 2016

Google shake-up; SMEs 4 the UPC; Europe warning; China insights and more from IPBC Global 2016 Day Two

All the plenary and breakout sessions have now come to an end at IPBC Global 2016. It’s been one hell of an event. IAM’s editorial team on the ground in Barcelona – editor Joff Wild (JW); North America editor Richard Lloyd (RL); Asia editor Jacob…

Read more

Frand/SEPS

View all
6 Jul 2021

European patent litigation makes Oppo an EPO opposition target

Chinese mobile players are well acquainted with validity fights in the US and China, but Oppo and others increasingly find themselves under attack at the EPO Read more

13 Aug 2020

EPO tussles between Huawei and Oppo raise eyebrows in China

Huawei has filed oppositions against rights acquired by Oppo and Xiaomi, and reaction shows that some hope to tamp down tensions between Chinese smartphone players Read more

12 Jun 2019

Group including Ericsson Nokia, InterDigital and Qualcomm releases SEP licence negotiation principles

Move designed to influence debate in Europe and comes on same day as implementers publish their own guidelines. Read more

14 May 2019

Why it's time for Europe to move beyond 5G's tired developers v implementers patent narrative

With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem Read more

Law & Policy

View all
17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

18 Mar 2021

EU Teva investigation shows IP’s competition law issues aren’t limited to patent litigation settlements

Commission’s move against the Israeli generic is unprecedented, but could be a sign of things to come Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

17 Dec 2020

What you need to know about post-Brexit changes to the UK’s SPC system

Failures to update IP management following the New Year could be costly for life sciences businesses Read more

Litigation

View all
6 Jul 2021

European patent litigation makes Oppo an EPO opposition target

Chinese mobile players are well acquainted with validity fights in the US and China, but Oppo and others increasingly find themselves under attack at the EPO Read more

18 Mar 2021

EU Teva investigation shows IP’s competition law issues aren’t limited to patent litigation settlements

Commission’s move against the Israeli generic is unprecedented, but could be a sign of things to come Read more

27 Oct 2020

Health insurer’s damages win against AstraZeneca creates new patent risks in The Netherlands

IP owners are liable to be sued by third parties if they assert rights that are subsequently invalidated, rules Dutch court. Read more

26 Oct 2020

French Court of Appeal SPC decision raises validity concerns

Merck IP right fails test in latest Article 3(a) judgment in case that may make France an even more attractive venue for nullity actions Read more

Market Developments

View all
15 Jun 2021

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators Read more

25 Mar 2021

Europe is seeing a boom in pharma and biotech patenting

A surge in life sciences applications offset a disappointing performance in other areas, the latest EPO statistics suggest Read more

17 Dec 2020

What you need to know about post-Brexit changes to the UK’s SPC system

Failures to update IP management following the New Year could be costly for life sciences businesses Read more

6 Oct 2020

Dividing UPC life sciences division would be a mistake, warns Bracco IP strategy chief

Splitting what should have been the London court’s competencies between Paris and Munich must only be a temporary fix, says Francesco Macchetta Read more

Non-Practising Entities

View all
6 Jul 2021

European patent litigation makes Oppo an EPO opposition target

Chinese mobile players are well acquainted with validity fights in the US and China, but Oppo and others increasingly find themselves under attack at the EPO Read more

9 Apr 2020

World leaders hatch further plans for accessibility of covid-19 IP rights

WHO to establish voluntary patent pool, while Greek Prime Minister calls for EU to buy rights to vaccines and tests Read more

6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

15 Jan 2020

Updated: Broad Institute faces tough fight in CRISPR patent appeal hearing

Oral hearings before the EPO’s Boards of Appeal may have a big impact on the European Cas9 landscape Read more

Patent Pools

View all
15 Sep 2020

Four key takeaways from the latest CRISPR patent wars decision

The Broad Institute gains key advantage in crucial interference battle at the PTAB Read more

9 Apr 2020

World leaders hatch further plans for accessibility of covid-19 IP rights

WHO to establish voluntary patent pool, while Greek Prime Minister calls for EU to buy rights to vaccines and tests Read more

24 Mar 2020

Covid-19 emergency may expose compulsory licensing limits

Government responses to the pandemic could include increased focus on obligatory sharing of patented inventions, but regulatory data exclusivities might serve as a barrier in both Europe and the United States. Read more

14 May 2019

Why it's time for Europe to move beyond 5G's tired developers v implementers patent narrative

With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem Read more

Patents Law

View all
6 Jul 2021

European patent litigation makes Oppo an EPO opposition target

Chinese mobile players are well acquainted with validity fights in the US and China, but Oppo and others increasingly find themselves under attack at the EPO Read more

17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

15 Jun 2021

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators Read more

12 Apr 2021

French SPC rulings give first signs of Royalty Pharma’s impact

Paris Court of Appeal turns down three appeals over supplementary protection certificate rejections Read more

Strategy

View all
18 Mar 2021

EU Teva investigation shows IP’s competition law issues aren’t limited to patent litigation settlements

Commission’s move against the Israeli generic is unprecedented, but could be a sign of things to come Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

17 Dec 2020

What you need to know about post-Brexit changes to the UK’s SPC system

Failures to update IP management following the New Year could be costly for life sciences businesses Read more

1 Dec 2020

A unitary EU SPC system may be on the cards, but it will be tough to achieve

Although life sciences companies would favour such a change, there are significant obstacles standing in the way of it happening Read more

Technology Licensing

View all
6 Jul 2021

European patent litigation makes Oppo an EPO opposition target

Chinese mobile players are well acquainted with validity fights in the US and China, but Oppo and others increasingly find themselves under attack at the EPO Read more

17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

15 Jun 2021

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators Read more

9 Feb 2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

A major milestone in the medical cannabinoid patent market has been passed Read more

Trade Secrets

View all
17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

24 Mar 2020

Covid-19 emergency may expose compulsory licensing limits

Government responses to the pandemic could include increased focus on obligatory sharing of patented inventions, but regulatory data exclusivities might serve as a barrier in both Europe and the United States. Read more

6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

Valuation

View all
15 Jun 2021

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators Read more

9 Feb 2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

A major milestone in the medical cannabinoid patent market has been passed Read more

19 Jan 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more